MedTrace Logo

Efficacy of Bone-marrow-derived and Placenta-derived Multipotent Mesenchymal Stem / Stromal Cells for Osteoarthritis

NCT04453111 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-07-07

No results posted yet for this study

Summary

To define the clinical effects of intra-articular transplantation of bone-marrow-derived (BM-MMSCs) and placenta-derived multipotent mesenchymal stem / stromal cells (P-MMSCs) for knee osteoarthritis.

Conditions

Interventions

BIOLOGICAL

Placenta-derived MMSCs

Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells

BIOLOGICAL

Bone marrow-derived MMSCs

Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells

DRUG

Hyalgan 20 mg in 2 ML Prefilled Syringe

Hyaluronic Acid 20 mg

Sponsors & Collaborators

  • The Institute of Traumatology and Orthopedics of NAMS of Ukraine

    collaborator UNKNOWN

  • Kyiv City Clinical Hospital № 6

    collaborator UNKNOWN

  • Institute of Cell Therapy

    lead INDUSTRY

Principal Investigators

  • Peter Nemtinov, MD · Institute of Cell Therapy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-02
Primary Completion
2021-08-31
Completion
2021-10-31

Countries

  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453111 on ClinicalTrials.gov